🔴 Atea Pharmaceuticals is trading 17.43% down in pre-market with no company-specific catalyst identified

Atea Pharmaceuticals is trading at $4.50, down 17.43%, with no new company-specific catalyst found to explain the decline.

• Latest identified announcement: its August 12, 2026 second-quarter update, including positive Phase 3 C-BEYOND results.
• No new August 28 company-specific filing, earnings release, FDA action, financing, or analyst downgrade was found.
• Broader markets were mixed, so macro sentiment does not clearly explain the isolated move.